2/2 Brain, Behavior and Genetic Studies of the 22q11 Deletion Studies

2/2 22q11 缺失研究的大脑、行为和遗传研究

基本信息

  • 批准号:
    8314057
  • 负责人:
  • 金额:
    $ 88.77万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-09-10 至 2015-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Brain-Behavior and Genetic Studies of the 22q11DS is a collaborative RO1 between Children's Hospital of Philadelphia (CHOP) and the University of Pennsylvania (Penn). The collaboration combines genetic and neurobiologic paradigms to advance understanding of the pathogenesis of schizophrenia (SCZ). CHOP has established the largest available sample of over 800 patients with 22q11DS who have been well characterized by genetics and genomics. There is a substantial risk for developing SCZ in adolescents and young adults with 22q11DS (23-30%), with illness presentation and course similar to SCZ in the general population (1%). Penn has extensive experience in brain-behavior studies in SCZ including phenotypic characterization, computerized neurocognitive testing, and neuroimaging measures that provide complementary quantitative phenotypes. The goal of the collaboration is to capitalize on this unique sample of 22q11DS and obtain neuropsychiatric, neurocognitive, and neuroimaging phenotypes of brain structure and function. The design will include age- stratified measures of brain structure with Magnetic Resonance Imaging (MRI) using volume-based morphometry, and connectivity with Diffusion Tensor Imaging (DTI). Functional MRI (fMRI) studies will examine brain circuitry activated in response to neurobehavioral probes (Specific Aim 1). The neuropsychiatric, neurobehavioral and neuroimaging phenotypes in 22q11DS will be compared to patients with SCZ, those at clinical and genetic risk for SCZ, and cardiac and healthy controls. These groups are needed to establish the profile of phenotypic features and quantitative brain-behavior measures and their interactions (Specific Aim 2). To establish genetic mechanisms producing the neuropsychiatric, neurobehavioral and neuroimaging phenotypes, association with common SNPs will be examined using a genome-wide approach and selected candidate genes. Associations of copy number variants (CNVs) with SCZ quantitative phenotypes will be tested in 22q11DS samples both across the genome and within the 22q11DS region. Deep next generation sequencing on the "non-deleted" allele will be performed for genes in the 22q11DS region and selected candidate genes in patients with the deletion to determine whether specific mutations or alleles are associated with extreme values of SCZ-related endophenotypes in 22q11DS individuals (Specific Aim 3). Specimens will be sent to the NIMH repository for transformation and DNA extraction. Data collection and quality control will be maintained and verified data will be regularly uploaded to the NIMH repository (Specific Aim 4). The proposed project will be the first of its kind to take a common deletion associated with SCZ and elucidate its behavioral, neurobiological and genetic substrates. Beyond the potential for yielding a better understanding of a severe manifestation of 22q11DS, the results will help identify pathways leading to SCZ in the general population in a way that will point to novel treatments. PUBLIC HEALTH RELEVANCE: Schizophrenia (SCZ) is a complex brain disorder with genetic substrates. It often emerges in adolescence and early adulthood with devastating effects. Of individuals with 22q11DS, 23-30% develops the SCZ phenotype, providing a unique opportunity to probe the pathogenesis of SCZ. Integration of genomics and neurobiology is key to understanding the causes of deficits, leading to early detection and advancing novel treatments.
描述(由申请人提供):22Q11DS的脑行为和遗传研究是费城儿童医院(CHOP)和宾夕法尼亚大学(Penn)之间的合作RO1。该协作结合了遗传学和神经生物学范式,以提高人们对精神分裂症(SCZ)发病机理的了解。 CHOP已建立了800多名具有遗传学和基因组学特征的22Q11D患者的最大样本。患有22q11ds(23-30%)的青少年和年轻人的SCZ存在很大的风险,疾病表现和类似于SCZ的一般人群(1%)。宾夕法尼亚州在SCZ的大脑行为研究中拥有丰富的经验,包括表型表征,计算机化的神经认知测试以及提供补充定量表型的神经成像措施。该协作的目的是利用这一独特的22q11ds样本,并获得大脑结构和功能的神经精神病,神经认知和神经影像型。该设计将包括使用基于体积的形态计量学的磁共振成像(MRI)的大脑结构的年龄分层测量,以及与扩散张量成像(DTI)的连通性。功能性MRI(fMRI)研究将检查对响应神经行为探针激活的脑回路(特定目标1)。将22Q11DS中的神经精神,神经行为和神经影像型表型与SCZ患者,SCZ的临床和遗传风险以及心脏和健康对照的患者进行比较。需要这些组来建立表型特征和定量脑行为措施及其相互作用的概况(特定目标2)。为了建立产生神经精神病,神经行为和神经成像表型的遗传机制,将使用全基因组方法和选定的候选基因检查与常见SNP的关联。拷贝数变体(CNV)与SCZ定量表型的关联将在整个基因组和22q11ds区域内的22q11ds样品中进行测试。将在22q11ds区域的基因和缺失患者中选定的候选基因进行“未删除”等位基因上的深层下一代测序,以确定特定突变或等位基因是否与22Q11DS个体中SCZ相关的内螺态的极端值有关(特定的AIM 3)。标本将发送到NIMH存储库进行转换和DNA提取。数据收集和质量控制将被维护,经过验证的数据将定期上传到NIMH存储库(特定的AIM 4)。拟议的项目将是第一个进行与SCZ相关的常见缺失并阐明其行为,神经生物学和遗传底物的一个。除了对22q11ds的严重表现有更好地理解的潜力之外,结果还将有助于识别导致普通人群中SCZ的途径,以指向新的治疗方法。 公共卫生相关性:精神分裂症(SCZ)是一种具有遗传底物的复杂脑疾病。它通常在青春期和成年早期出现,并具有毁灭性的影响。在22q11ds的个体中,23-30%的人发展了SCZ表型,提供了一个独特的机会来探测SCZ的发病机理。基因组学和神经生物学的整合是理解赤字原因的关键,导致早期发现并推进新的治疗方法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

BEVERLY S EMANUEL其他文献

BEVERLY S EMANUEL的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('BEVERLY S EMANUEL', 18)}}的其他基金

Molecular Dissection of the 22q11.2 Deletion Syndrome
22q11.2 缺失综合征的分子解剖
  • 批准号:
    10473894
  • 财政年份:
    2018
  • 资助金额:
    $ 88.77万
  • 项目类别:
Molecular Dissection of the 22q11.2 Deletion Syndrome
22q11.2 缺失综合征的分子解剖
  • 批准号:
    10296523
  • 财政年份:
    2018
  • 资助金额:
    $ 88.77万
  • 项目类别:
Molecular Dissection of the 22q11.2 Deletion Syndrome
22q11.2 缺失综合征的分子解剖
  • 批准号:
    9763601
  • 财政年份:
    2018
  • 资助金额:
    $ 88.77万
  • 项目类别:
2/2 Brain, Behavior and Genetic Studies of the 22q11 Deletion Studies
2/2 22q11 缺失研究的大脑、行为和遗传研究
  • 批准号:
    8690149
  • 财政年份:
    2010
  • 资助金额:
    $ 88.77万
  • 项目类别:
2/2 Brain, Behavior and Genetic Studies of the 22q11 Deletion Studies
2/2 22q11 缺失研究的大脑、行为和遗传研究
  • 批准号:
    7985951
  • 财政年份:
    2010
  • 资助金额:
    $ 88.77万
  • 项目类别:
2/2 Brain, Behavior and Genetic Studies of the 22q11 Deletion Studies
2/2 22q11 缺失研究的大脑、行为和遗传研究
  • 批准号:
    8479435
  • 财政年份:
    2010
  • 资助金额:
    $ 88.77万
  • 项目类别:
2/2 Brain, Behavior and Genetic Studies of the 22q11 Deletion Studies
2/2 22q11 缺失研究的大脑、行为和遗传研究
  • 批准号:
    8141258
  • 财政年份:
    2010
  • 资助金额:
    $ 88.77万
  • 项目类别:
CORE--MOLECULAR GENETICS CORE
核心--分子遗传学核心
  • 批准号:
    7670393
  • 财政年份:
    2008
  • 资助金额:
    $ 88.77万
  • 项目类别:
Chromosomal Rearrangements and Cardiac Candidate Genes
染色体重排和心脏候选基因
  • 批准号:
    7354823
  • 财政年份:
    2007
  • 资助金额:
    $ 88.77万
  • 项目类别:
Core--Cell Culture, DNA and Microarray
核心--细胞培养、DNA和微阵列
  • 批准号:
    7354825
  • 财政年份:
    2007
  • 资助金额:
    $ 88.77万
  • 项目类别:

相似海外基金

Genetic modifiers of congenital heart disease in 22q11.2 deletion syndrome
22q11.2缺失综合征先天性心脏病的遗传修饰
  • 批准号:
    10373375
  • 财政年份:
    2022
  • 资助金额:
    $ 88.77万
  • 项目类别:
Project II - Modeling meningomyelocele in frog using human alleles and folic acid exposure
项目 II - 使用人类等位基因和叶酸暴露模拟青蛙脑膜脊髓膨出
  • 批准号:
    10154466
  • 财政年份:
    2020
  • 资助金额:
    $ 88.77万
  • 项目类别:
Project II - Modeling meningomyelocele in frog using human alleles and folic acid exposure
项目 II - 使用人类等位基因和叶酸暴露模拟青蛙的脑膜脊髓膨出
  • 批准号:
    10300071
  • 财政年份:
    2020
  • 资助金额:
    $ 88.77万
  • 项目类别:
Project II - Modeling meningomyelocele in frog using human alleles and folic acid exposure
项目 II - 使用人类等位基因和叶酸暴露模拟青蛙的脑膜脊髓膨出
  • 批准号:
    10533747
  • 财政年份:
    2020
  • 资助金额:
    $ 88.77万
  • 项目类别:
Olfactory and facial markers of developmental risk for psychosis in 22q11 deletion syndrome
22q11 缺失综合征精神病发育风险的嗅觉和面部标记
  • 批准号:
    10217017
  • 财政年份:
    2019
  • 资助金额:
    $ 88.77万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了